16 min

Emerging Therapies: Phase 3 Efficacy & Safety Data Easing the Disease Burden of Patients with Atopic Dermatitis

    • Medicine

JAK-STAT inhibitors: oral and topical
JAK-STAT inhibitors vs dupilumab
IL-13 antagonists
IL-31 antagonists

  • Annenberg Center for Health Sciences

JAK-STAT inhibitors: oral and topical
JAK-STAT inhibitors vs dupilumab
IL-13 antagonists
IL-31 antagonists

16 min

  • Annenberg Center for Health Sciences